Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 84 people in total — 44 received a medicine called nintedanib and 40 received a placebo (a dummy treatment with no active ingredient). The trial was measuring "progression-free survival" (PFS) — that is, the estimated chance that a participant's cancer had not grown or spread by certain points in time. The main goal was to look at this figure at 36 weeks (roughly 9 months) after starting treatment. The reported data shows that at 36 weeks, the estimated probability of being progression-free was 15.6% in the nintedanib group compared with 2.9% in the placebo group. At earlier time points, the reported figures were closer together: at 12 weeks the probabilities were 45.3% (nintedanib) and 46.2% (placebo), and at 24 weeks they were 26.7% (nintedanib) and 17.3% (placebo). When looking at how long it took for the cancer to progress — measured in days using scan-based assessments, a blood marker called CA-125, or a combination of both — the reported median times were similar across both groups, ranging from roughly 83 to 86 days for the scan and blood-marker measures, with a longer figure of 143 days (nintedanib) versus 85 days (placebo) for the combined measure. No deaths were recorded during the trial, so no time-to-death figures were reported. The trial also collected information about side effects and abnormal laboratory results, though the full breakdown of those categories was not labelled in the submitted data in a way that allows each number to be matched to a specific event. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 37185961) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You are a woman who has been diagnosed (confirmed by lab testing) with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer of the serous type that has come back, and your cancer responded to your 2nd, 3rd, or 4th round of chemotherapy.
- Your cancer responded to treatment, meaning your CA125 blood marker dropped by at least 50%, or your tumors shrank or disappeared based on scans.
- Less than 12 months have passed since you started your most recent chemotherapy for your returned cancer.
- You have fully recovered, or recovered as much as possible, from the side effects of any previous chemotherapy or radiation treatment.
- You are older than 18 years of age.
- Your doctor expects you to live for at least 3 more months.
- You are well enough to carry out normal daily activities with little or no difficulty (confirm with trial site).
- Your liver is working well enough, based on blood test results within accepted ranges.
- Your kidneys are working well enough, based on blood test results within accepted ranges.
- Your blood counts (white blood cells, platelets, and hemoglobin) are at acceptable levels.
- You are willing and able to sign a written consent form agreeing to take part in the trial.
- It has been more than 4 weeks but less than 8 weeks since your last chemotherapy, hormonal treatment (other than hormone replacement therapy), or immunotherapy.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have a serious illness or condition unrelated to cancer, such as a neurological, psychiatric, or infectious disease, active skin or stomach ulcers, or abnormal lab results that could make participation risky.
- You have had major surgery or a serious injury in the past 4 weeks and have not fully healed, or you are planning to have surgery during the study.
- You have had an allergic reaction to the study drug (BIBF 1120) or any of its ingredients before.
- You have significant heart or blood pressure problems, such as uncontrolled high blood pressure, unstable chest pain, a heart attack in the past 9 months, or moderate-to-severe heart failure.
- You have had a serious bleeding event or a blood clot in the past 12 months, or you have an inherited condition that increases your risk of bleeding or clotting.
- You currently need to take full-dose blood-thinning (anticoagulant) medication.
- You have a stomach or bowel condition that would prevent you from properly absorbing the study drug.
- Your cancer has spread to your brain or the lining around your brain or spinal cord.
- You have taken part in another clinical trial or received an experimental drug within the past 4 weeks, or are currently doing so.
- You have received chemotherapy, radiation, or immunotherapy within the past 4 weeks.
- You are unable or unwilling to follow the requirements of the study.
- You currently have an active problem with alcohol or drug misuse.
- You have had another type of cancer (other than certain minor skin cancers) within the past 5 years.
- You are not confirmed to be unable to become pregnant (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
PFS Rate at 36 Weeks (After 9 Months)
Other options
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.